Intensity Therapeutics, Inc.
INTSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Intensity Therapeutics, Inc. (INTS) is listed under Biotechnology. With a market capitalization of $13.4M, it sits in micro-cap territory. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials.
Market Cap
$13.4M
Beta
3.03
P/E (TTM)
—
P/E (Fwd)
-2.06
EPS (TTM)
$-2.00
EPS (Fwd)
$-1.99
ROE
-195.9%
ROA
-89.9%
Cash
$9.5M
Total Debt
$95,000
Free CF
-$6.3M
52W Change
-42.0%
Annual Financials
Cash vs Debt
Where INTS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, INTS finished 25.65% below its 150-day moving average ($5.38) and 39.94% below its 200-day moving average ($6.66). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INTS overbought or oversold?
At the September 3, 2026 close, INTS's RSI(14) was 50.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Intensity Therapeutics, Inc. holds $9.5M in cash against $95K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$6.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -195.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
Intensity Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing INTS's risk profile alongside its fundamentals and technical indicators provides a more complete picture.